Abstract
Retinal blindness is an important cause of pediatric visual loss. Leber’s congenital amaurosis (LCA) is one of these causes, often wrongly included in the spectrum of retinitis pigmentosa. The disease has become the center of research after initial reports of success in management with gene therapy. This review discusses in brief the clinical presentation and investigative modalities used in LCA. Further, the road to gene discovery and details of currently applied gene therapy are presented. LCA is one of the first successfully managed human diseases and offers an entirely new dimension in ocular therapeutics.
Similar content being viewed by others
References
Cantani A, Bellioni P, Bamonte G, Salvinelli F, Bamonte MT. Seven hereditary syndromes with pigmentary retinopathy. a review and differential diagnosis. Clin Pediatr (Phila). 1985;24:578–83.
Gregory-Evans K, Pennesi ME, Weleber RG. Retinitis pigmentosa and allied disorders. In: Ryan SJ, editor. Retina. Chapter 40. 5th ed. New York: Elsevier; 2013. p. 761–835.
Shintani K, Shechtman DL, Gurwood AS. Review and update: current treatment trends for patients with retinitis pigmentosa. Optometry. 2009;80:384–401.
Trichonas G, Traboulsi EI, Ehlers JP. Correlation of ultra-widefield fundus autofluorescence patterns with the underlying genotype in retinal dystrophies and retinitis pigmentosa. Ophthalmic Genet. 2016;23:1–5.
Leber T. Ueber retinitis pigmentosa und angeborene amaurose. Archiv für Opthalmologie. 1869;15:1–25.
Leber T. Die Krankheiten der Netzhaut. In: Saemish T, editor. Graefe Handbuch der gesamten Augenheilkunde. 2nd ed. Leipzig: W. Engelman; 1916. p. 1076–225.
Paunescu K, Wabbels B, Preising MN, Lorenz B. Longitudinal and cross-sectional study of patients with early-onset severe retinal dystrophy associated with RPE65 mutations. Graefes Arch Clin Exp Ophthalmol. 2005;243:417–26.
Weleber RG, Michaelides M, Trzupek KM, Stover NB, Stone EM. The phenotype of severe early childhood onset retinal dystrophy (SECORD) from mutation of RPE65 and differentiation from Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2011;52:292–302.
Franceschetti A, Dieterlé P. Importance diagnostique et pronostique de l’électrorétinogramme (ERG) dans les dégénérescences tapéto-rétiniennes avec rétrécissement du champ visuel et héméralopie. Confinia Neurol. 1954;14:184–6.
Koenekoop RK. An overview of Leber congenital amaurosis: model to understand human retinal development. Surv Ophthalmol. 2004;49:379–98.
den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog Retin Eye Res. 2008;27:391–419.
Pinckers AJL. Leber’s congenital amaurosis as conceived by Leber. Ophthalmologica. 1979;179:48–51.
Alkharashi M, Fulton AB. Available evidence on leber congenital amaurosis and gene therapy. Semin Ophthalmol. 2017;32:14–21.
Arcot Sadagopan K, Battista R, Keep RB, Capasso JE, Levin AV. Autosomal-dominant Leber congenital amaurosis caused by a heterozygous CRX mutation in a father and son. Ophthalmic Genet. 2015;36:156–9.
Redmond TM, Yu S, Lee E, et al. Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle. Nat Genet. 1998;20:344–51.
Perrault I, Rozet JM, Calvas P, et al. Retinal-specific guanylate cyclase gene mutations in Leber’s congenital amaurosis. Nat Genet. 1996;14:61–4.
Freund CL, Wang QL, Chen S, et al. De novo mutations in the CRX homeobox gene associated with Leber congenital amaurosis. Nat Genet. 1998;18:311–2.
Franceschetti A. Rubéola pendant la grossesse et cataracte congenitale chez l’enfant, accompagnée du phenomène digito-oculaire. Ophthalmologica. 1947;114:332–9.
Elder MJ. Leber congenital amaurosis and its association with keratoconus and keratoglobus. J Pediatr Ophthalmol Strabismus. 1994;31:38–40.
Foxman SG, Heckenlively JR, Bateman JB, et al. Classification of congenital and early onset retinitis pigmentosa. Arch Ophthalmol. 1985;103:1502–6.
Van Hooser JP, Aleman TS, He YG, et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci U S A. 2000;97:8623–8.
Zhang T, Baehr W, Fu Y. Chemical chaperone TUDCA preserves cone photoreceptors in a mouse model of Leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2012;53:3349–56.
Yang F, Ma H, Belcher J, et al. Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration. FASEB J. 2016;30:4313–25.
Waardenburg PJ, Schappert-Kimmijser J. On various recessive biotypes of Leber's congenital amaurosis. Acta Ophthalmol. 1963;41:317–20.
Wang SY, Zhang Q, Zhang X, Zhao PQ. Comprehensive analysis of genetic variations in strictly-defined Leber congenital amaurosis with whole-exome sequencing in Chinese. Int J Ophthalmol. 2016;9:1260–4.
Chacon-Camacho OF, Zenteno JC. Review and update on the molecular basis of Leber congenital amaurosis. World J Clin Cases. 2015;3:112–24.
Li Y, Wang H, Peng J, et al. Mutation survey of known LCA genes and loci in the Saudi Arabian population. Invest Ophthalmol Vis Sci. 2009;50:1336–43.
Perrault I, Rozet JM, Calvas P, et al. Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet. 1996;14:461–4.
Marlhens F, Bareil C, Griffoin JM, et al. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet. 1997;17:139–41.
Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med. 2008;358:2240–8.
Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231–9.
Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A. 2008;105:15112–7.
Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther. 2008;19:979–90.
Maguire AM, High KA, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber’s congenital amaurosis: a phase 1 dose-escalation trial. Lancet. 2009;374:1597–605.
Testa F, Maguire AM, Rossi S, et al. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2. Ophthalmology. 2013;120:1283–91.
Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med. 2012;4:120ra15.
Bennett J, Wellman J, Marshall KA, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661–72.
Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372:1887–97.
Cideciyan AV, Hauswirth WW, Aleman TS, et al. Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year. Hum Gene Ther. 2009;20:999–1004.
Georgiadis A, Duran Y, Ribeiro J, et al. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Ther. 2016;23:857–62.
Chacón-Camacho ÓF, Astorga-Carballo A, Zenteno JC. Gene therapy for hereditary ophthalmological diseases: advances and future perspectives. [Article in Spanish]. Gac Med Mex. 2015;151:501–11.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
All the authors contributed to concept and outline of the review. BT and PV wrote and critically revised the manuscript, BT and PB performed the review of literature. PV will act as guarantor for the paper.
Compliance with Ethical Standards
ᅟ
Conflict of Interest
None.
Source of Funding
None.
Rights and permissions
About this article
Cite this article
Takkar, B., Bansal, P. & Venkatesh, P. Leber’s Congenital Amaurosis and Gene Therapy. Indian J Pediatr 85, 237–242 (2018). https://doi.org/10.1007/s12098-017-2394-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-017-2394-1